Drug Insight: gastrointestinal stromal tumors (GIST)--the solid tumor model for cancer-specific treatment
Related Experiment Video
Updated: Jul 7, 2026
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
Stefan Sleijfer1, Erik Wiemer, Jaap Verweij
1Department of Medical Oncology, Erasmus University Medical Centre, Rotterdam, The Netherlands. s.sleijfer@erasmusmc.nl
Abstract:
We are living in an exciting era in the treatment of cancer, using drugs that target specific proteins rather than agents that cause more general cytotoxic effects. The identification of proteins and signal transduction pathways that play crucial roles in the pathogenesis of cancer has allowed treatments to be designed that target these tumor-driven events. Gastrointestinal stromal tumors (GIST) are rare mesenchymal tumors and were among the first solid tumor types for which such a novel treatment (in this case imatinib) became available. The tyrosine kinase inhibitor imatinib targets the human KIT receptor and the platelet-derived growth factor receptor-alpha. This drug exhibits impressive antitumor effects against GIST and has become the first-line therapy for advanced disease. Major insights into the mechanism of action of this drug, drug resistance, and patient management issues have been gleaned. Additionally, new drugs developed for the treatment of GIST have been identified. As a consequence, lessons learned from GIST are widely applicable to other tumor entities, thereby rendering GIST the paradigm of solid tumors treated with tyrosine kinase inhibitors. This Review discusses the pathogenesis of GIST, treatment strategies, mechanisms accounting for drug resistance, and potential future perspectives.
Insights
Targeted cancer therapies, like imatinib for gastrointestinal stromal tumors (GIST), represent a paradigm shift. Understanding GIST treatment and resistance mechanisms offers broad insights for other solid tumors.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Targeted therapies represent a significant advancement over traditional cytotoxic chemotherapy in cancer treatment.
- Gastrointestinal stromal tumors (GIST) were among the first solid tumors to benefit from targeted therapy, specifically imatinib.
Purpose of the Study:
- To review the pathogenesis, treatment strategies, and drug resistance mechanisms in GIST.
- To highlight GIST as a model for understanding tyrosine kinase inhibitor (TKI) therapy in solid tumors.
Main Methods:
- Review of existing literature on GIST pathogenesis and treatment.
- Analysis of imatinib's mechanism of action, resistance patterns, and clinical management.
- Discussion of emerging therapies and future directions in GIST research.
Main Results:
- Imatinib, a tyrosine kinase inhibitor targeting KIT and PDGFRA, is highly effective as first-line therapy for advanced GIST.
- Significant insights have been gained into imatinib's mechanism of action and the development of drug resistance.
- New therapeutic agents for GIST have been identified, expanding treatment options.
Conclusions:
- GIST serves as a paradigm for targeted therapy with TKIs in solid tumors.
- Lessons learned from GIST management are applicable to other cancer types.
- Continued research into GIST pathogenesis and resistance is crucial for advancing cancer treatment.
